

Stereochemistry abstracts

Jennifer A. Chaplin,* Michael D. Levin, Brian Morgan, Nancy Farid, Jen Li, Zuolin Zhu, Jeff McQuaid, Lawrence W. Nicholson, Cynthia A. Rand and Mark J. Burk

Tetrahedron: Asymmetry 15 (2004) 2793




(*R*)-*N*-Formyl-4-fluorophenylglycine

$[\alpha]_D^{25} = -204.3$ (*c* 1.012, MeOH)
 Ee = 99.8% (determined by chiral HPLC)
 Absolute configuration: *R*

Maria I. Monterde, Murielle Lombard, Alain Archelas, Annette Cronin, Michael Arand and Roland Furstoss*

Tetrahedron: Asymmetry 15 (2004) 2801




(*R*)-1-(3-Chlorophenyl)-1,2-ethanediol

Ee = 97%
 $[\alpha]_D^{22} = -23.4$ (*c* 1.55, EtOH)
 Source of chirality: enzymatic resolution using *Solanum tuberosum* epoxide hydrolase
 Absolute configuration: *R*

Ben S. Morgan, Dorothée Hoenner, Paul Evans and Stanley M. Roberts*

Tetrahedron: Asymmetry 15 (2004) 2807




$\text{C}_{13}\text{H}_{16}\text{O}_2\text{S}$
 (3*S*,4*S*)-3-Benzylsulfanyl-4-hydroxy-cyclohexanone

Ee >99% (HPLC)
 $[\alpha]_D = +5.5$ (*c* 1.65, CHCl_3)
 Source of chirality: enzymatic kinetic resolution
 Absolute configuration: (3*S*,4*S*)


Ben S. Morgan, Dorothée Hoenner, Paul Evans and Stanley M. Roberts*

Tetrahedron: Asymmetry 15 (2004) 2807



$\text{C}_{15}\text{H}_{18}\text{O}_3\text{S}$
 (3*R*,4*R*)-3-Benzylsulfanyl-4-hydroxy-4-acetoxy-cyclohexanone


Ee >99% (HPLC)
 $[\alpha]_D = -31.9$ (*c* 1.0, CHCl_3)
 Source of chirality: enzymatic kinetic resolution
 Absolute configuration: (3*R*,4*R*)



C₁₂H₁₂OS
(S)-4-Benzylsulfanyl-cyclopent-2-enone


Ee >99% (HPLC)
[α]_D = +178 (*c* 1.0, CHCl₃)

Source of chirality: enzymatic kinetic resolution
Absolute configuration: (4*S*)




C₁₂H₁₄O₂S
(3*S*,4*S*)-3-Benzylsulfanyl-4-hydroxy-cyclopentanone

Ee >99% (HPLC)
[α]_D = -60 (*c* 1.0, CHCl₃)
Source of chirality: enzymatic kinetic resolution
Absolute configuration: (3*S*,4*S*)




C₃₁H₆₀O₃S₂
(2*S*)-3-Hydroxy-2-[(2-undecyl-1,3-dithian-2-yl)methyl]propyl laurate

Source of chirality: enzymatic transformation
E.e.: 97%
[α]_D²⁰ = +5.3 (*c* 0.38, CHCl₃)
Absolute configuration: 2*S*




C₃₅H₆₈O₂S₂
(2*S*)-3-Hydroxy-2-[(2-pentadecyl-1,3-dithian-2-yl)methyl]propyl laurate

Source of chirality: enzymatic transformation
E.e.: 95%
[α]_D²⁰ = -3.6 (*c* 0.74, CHCl₃)
Absolute configuration: 2*S*




$C_{21}H_{42}O_2S_2$
(*2R*)-3-(Dodecyloxy)-2-[(2-methyl-1,3-dithian-2-yl)methyl]propan-1-ol

Source of chirality: enzymatic resolution
E.e.: 96%
 $[\alpha]_D^{20} = +2.2$ (*c* 0.68, CHCl₃)
Absolute configuration: 2*R*




$C_{13}H_{15}NO_5$
Methyl 2-aminocarbonyl-2-methyl-3-(3,4-methylenedioxy)phenylpropionate

Ee = 98.2%
 $[\alpha]_D^{22} = -7.3$ (*c* 0.75, EtOH)
Source of chirality: enzymatic desymmetrization
Absolute configuration: (*R*)




$C_{14}H_{17}NO_6$
Methyl 2-methyl-3-(3,4-methylenedioxy)phenyl-2-methoxycarbonylaminopropionate

Ee = 98.4%
 $[\alpha]_D^{24} = -27.9$ (*c* 0.57, EtOH)
Source of chirality: enzymatic desymmetrization
Absolute configuration: (*S*)



$C_{10}H_{17}ClO_4$
t-Butyl (*R*)-6-chloro-5-hydroxy-3-oxohexanoate

Ee = 94%
 $[\alpha]_D = +22.8$ (*c* 1.6, CHCl₃)
Source of chirality: enzymatic reduction
Absolute configuration: (5*R*)




C₁₄H₃₀O₂Si
2-Dimethylhexylsiloxo-(1*R*,2*S*)-cyclohexanol

Ee = >98%

[α]_D²³ = +10.6 (c 1.0, CHCl₃)

Source of chirality: enzymatic oxidation

Absolute configuration: (1*R*,2*S*)




C₇H₉BrO₂S
1-Bromo-4-thiomethyl-(2*R*,3*S*)-dihydroxycyclohexa-4,6-diene

Ee = >98%

[α]_D¹⁹ = -10.0 (c 1.08, CHCl₃)

Source of chirality: enzymatic oxidation

Absolute configuration: (2*R*,3*S*)




C₁₅H₃₀O₂SSi
2-Dimethylhexylsiloxo-(1*S*,2*S*)-6-thiomethyl-cyclohex-5-ene

Ee = >98%

[α]_D²² = -41.5 (c 0.84, CHCl₃)

Source of chirality: enzymatic oxidation

Absolute configuration: (1*S*,2*S*)



C₇H₁₀O₂S
1-Thiomethyl-(2*S*,3*S*)-dihydroxycyclohexa-4,6-diene

Ee = >98%

[α]_D²⁴ = +81.3 (c 0.27, MeOH)

Source of chirality: enzymatic oxidation

Absolute configuration: (2*S*,3*S*)




C₇H₁₂O₂S
1-Thiomethyl-(2*S*,3*S*)-dihydroxycyclohex-6-ene

Ee = >98%

[α]_D²⁴ = -104 (c 0.75, CHCl₃)

Source of chirality: enzymatic oxidation

Absolute configuration: (2*S*,3*S*)




C₃₀H₂₆NOP
(3a*R*,8a*S*)-2-(2'-Di-*p*-tolylphosphino)phenyl-3a,8a-dihydro-8*H*-indeno[1,2-d]oxazole

Source of chirality: (1*R*,2*S*)-1-amino-2-indanol

[α]_D²⁵ = +145 (c 1.22, CHCl₃)

Absolute configuration: 3a*R*,8a*S*




C₁₂H₁₂O₄
(1*R*,2*R*,3*S*,4*S*)-4-Acetoxy-2,3-epoxy-1,2,3,4-tetrahydronaphthalen-1-ol

Ee = >95%

[α]_D²⁴ = +4.0 (c 1.0, CH₂Cl₂)

Source of chirality: enzymatic desymmetrization

Absolute configuration: (1*R*,2*R*,3*S*,4*S*)




C₁₈H₂₆O₄Si
(1*S*,2*S*,3*S*,4*R*)-1-Acetoxy-4-(tert-butyldimethylsilyloxy)-2,3-epoxy-1,2,3,4-tetrahydronaphthalene

Ee = >95%

[α]_D²⁴ = -22.0 (c 1.5, CH₂Cl₂)

Source of chirality: enzymatic desymmetrization

Absolute configuration: (1*S*,2*S*,3*S*,4*R*)




$C_{16}H_{24}O_3Si$
(1S,2S,3S,4R)-2,3-Epoxy-4-(*tert*-butyldimethylsilyloxy)-1,2,3,4-tetrahydronaphthalene-1-o1

Ee = >95%

 $[\alpha]_D^{24} = -18.0$ (*c* 1.0, CH₂Cl₂)

Source of chirality: enzymatic desymmetrization


Absolute configuration: (1*S*,2*S*,3*S*,4*R*)

$C_{12}H_{11}ClO_3$
(1S,2S,3S,4S)-1-Acetoxy-4-chloro-2,3-epoxy-1,2,3,4-tetrahydronaphthalene

Ee = >95%

 $[\alpha]_D^{24} = +109$ (*c* 1.27, CH₂Cl₂)

Source of chirality: enzymatic desymmetrization


Absolute configuration: (1*S*,2*S*,3*S*,4*S*)

$C_{19}H_{18}O_5$
(1S,2*R*,3*S*,4*S*)-4-Acetoxy-8-benzyloxy-2,3-epoxy-1,2,3,4-tetrahydronaphthalene-1-o1

Ee = >95%

 $[\alpha]_D^{24} = +58.4$ (*c* 0.46, CH₂Cl₂)

Source of chirality: enzymatic desymmetrization

Absolute configuration: (1*R*,2*R*,3*S*,4*R*)


$C_{17}H_{16}O_4$
(1S,2*S*,3*R*,4*R*)-8-Benzyl-2,3-epoxy-1,2,3,4-tetrahydronaphthalene-1,4-diol

Ee = >95%

 $[\alpha]_D^{24} = -26.5$ (*c* 2.5, CH₂Cl₂)

Source of chirality: enzymatic desymmetrization


Absolute configuration: (1*S*,2*S*,3*R*,4*R*)

 $C_{16}H_{20}O_5$ (1*R*,2*R*,3*S*,4*S*)-4-Acetoxy-5,8-diallyloxy-2,3-epoxy-1,2,3,4-tetrahydronaphthalen-1-ol

Ee = >98%

 $[\alpha]_D^{21} = -28.2$ (*c* 1.0, CHCl₃)


Source of chirality: enzymatic desymmetrization

Absolute configuration: (1*R*,2*R*,3*S*,4*S*) $C_{19}H_{16}O_6$ (1*S*,2*S*,3*R*,4*R*)-1-Acetoxy-4,5-benzylidenedioxy-2,3-epoxy-1,2,3,4-tetrahydronaphthalen-8-ol

Ee = >98%

 $[\alpha]_D^{21} = -139$ (*c* 1.0, CHCl₃)


Source of chirality: enzymatic desymmetrization

Absolute configuration: (1*S*,2*S*,3*R*,4*R*) $C_{20}H_{28}O_2$ Z-(3*S*)-3-Benzylxyloxy-6,10-dimethylundeca-5,9-dien-2-one

Ee >95%


 $[\alpha]_D^{25} = -18.0$ (*c* 1.0, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (3*S*)(R)-α-Methoxyphenylacetic acid *Z*-(1*R*,8*R*)-1-acetyl-9-(tert-butyldimethylsilyloxy)-4,8-dimethylnon-3-enyl ester

Ee >99%, de >95% (C1), de = 21% (C8)

 $[\alpha]_D^{25} = -19$ (*c* 1, CHCl₃)Source of chirality: asymmetric synthesis,
resolution of diastereomersAbsolute configuration: (α*R*,1*R*,8*R*)




(*R*)- α -Methoxyphenylacetic acid *Z*-(1*S*,8*R*)-1-acetyl-9-(*tert*-butyldimethylsilyloxy)-4,8-dimethylnon-3-enyl ester

Ee >99%, de >98% (C1), de = 21% (C8)

$[\alpha]_D^{25} = -23.9$ (*c* 0.91, CHCl₃)

Source of chirality: asymmetric synthesis,
resolution of diastereomers

Absolute configuration: (α *R*,1*S*,8*R*)




(+)-(4-Hydroxy-3-methoxy-5-oxo-2,5-dihydrofuran-2-yl)-acetic acid methyl ester

Ee = 95%

$[\alpha]_D^{21} = +40$ (*c* 1, MeOH)

Source of chirality: enzymatic resolution




(-)-(4-Hydroxy-3-methoxy-5-oxo-2,5-dihydrofuran-2-yl)-acetic acid

Ee = 92%

$[\alpha]_D^{21} = -28$ (*c* 1, MeOH)

Source of chirality: enzymatic resolution




(+)-(3-Ethyl-4-hydroxy-5-oxo-2,5-dihydrofuran-2-yl)-acetic acid ethyl ester

Ee = 97%

$[\alpha]_D^{21} = +21$ (*c* 1, EtOH)

Source of chirality: enzymatic resolution




(−)-(3-Ethyl-4-hydroxy-5-oxo-2,5-dihydrofuran-2-yl)-acetic acid

Ee = 97%

 $[\alpha]_D^{25} = -26$ (*c* 1, MeOH)


Source of chirality: enzymatic resolution

(1*R*,2*S*)-2-Aminocyclopent-3-ene-carboxylic acid

Ee = 96% by GC on a Chirasil-L-Val column after double derivatization

 $[\alpha]_D^{25} = +96.7$ (*c* 0.3, H₂O)


Source of chirality: lipolase-catalysed enantioselective ring opening

Absolute configuration: (1*R*,2*S*)(1*R*,2*S*)-2-Aminocyclohex-3-ene-carboxylic acid

Ee = 98% by GC on a Chirasil-L-Val column after double derivatization

 $[\alpha]_D^{25} = +121.1$ (*c* 0.5, H₂O)

Source of chirality: lipolase-catalysed enantioselective ring opening


Absolute configuration: (1*R*,2*S*)(1*R*,2*S*)-2-Aminocyclohex-4-ene-carboxylic acid

Ee = 99% by GC on a Chirasil-L-Val column after double derivatization

 $[\alpha]_D^{25} = -38.8$ (*c* 0.5, H₂O)

Source of chirality: lipolase-catalysed enantioselective ring opening

Absolute configuration: (1*R*,2*S*)




C₉H₁₅NO₂
(1*R*,2*S*)-2-Aminocyclooct-5-ene-carboxylic acid

Ee = 95% by GC on a CP-Chirasil-Dex CB column

[α]_D²⁵ = +23.9 (*c* 0.3, H₂O)

Source of chirality: lipolase-catalysed enantioselective ring opening

Absolute configuration: (1*R*,2*S*)




C₆H₁₀ClNO₂
(1*R*,2*S*)-2-Aminocyclopent-3-ene-carboxylic acid hydrochloride

Ee = 99% by GC on a Chirasil-L-Val column after double derivatization

[α]_D²⁵ = +81.6 (*c* 0.3, H₂O)

Source of chirality: lipolase-catalysed enantioselective ring opening

Absolute configuration: (1*R*,2*S*)




C₇H₁₂ClNO₂
(1*R*,2*S*)-2-Aminocyclohex-3-ene-carboxylic acid hydrochloride

Ee = 99% by GC on a Chirasil-L-Val column after double derivatization

[α]_D²⁵ = +121.7 (*c* 0.4, H₂O)

Source of chirality: lipolase-catalysed enantioselective ring opening

Absolute configuration: (1*R*,2*S*)




C₇H₁₂ClNO₂
(1*R*,2*S*)-2-Aminocyclohex-4-ene-carboxylic acid hydrochloride

Ee = 99% by GC on a Chirasil-L-Val column after double derivatization

[α]_D²⁵ = -26 (*c* 0.25, H₂O)

Source of chirality: lipolase-catalysed enantioselective ring opening

Absolute configuration: (1*R*,2*S*)




$C_9H_{16}ClNO_2$
(1*R*,2*S*)-2-Aminocyclooct-5-ene-carboxylic acid hydrochloride

Ee = 95% by GC on a CP-Chirasil-Dex
CB column

$[\alpha]_D^{25} = +14.2$ (*c* 0.35, H₂O)

Source of chirality: lipolase-catalysed
enantioselective ring opening

Absolute configuration: (1*R*,2*S*)




C_6H_7NO
(1*S*,5*R*)-6-Azabicyclo[3.2.0]hept-3-en-7-one

Ee = 99% by GC on a CP-Chirasil-Dex
CB column

$[\alpha]_D^{25} = -34.8$ (*c* 0.45, CHCl₃)

Source of chirality: lipolase-catalysed
enantioselective ring opening

Absolute configuration: (1*S*,5*R*)




C_7H_9NO
(1*S*,6*R*)-7-Azabicyclo[4.2.0]oct-4-en-8-one

Ee = 99% by GC on a CP-Chirasil-Dex
CB column

$[\alpha]_D^{25} = +161.1$ (*c* 0.45, CHCl₃)

Source of chirality: lipolase-catalysed
enantioselective ring opening

Absolute configuration: (1*S*,6*R*)




C_7H_9NO
(1*S*,6*R*)-7-Azabicyclo[4.2.0]oct-3-en-8-one

Ee = 99% by GC on a CP-Chirasil-Dex
CB column

$[\alpha]_D^{25} = -29.1$ (*c* 0.45, CHCl₃)

Source of chirality: lipolase-catalysed
enantioselective ring opening

Absolute configuration: (1*S*,6*R*)




$C_9H_{13}NO$
(*1S,8R*)-9-Azabicyclo[6.2.0]oct-4-en-10-one

Ee = 99% by GC on a CP-Chirasil-Dex CB column

$[\alpha]_D^{25} = -24.9$ (*c* 0.4, CHCl₃)

Source of chirality: lipolase-catalysed enantioselective ring opening

Absolute configuration: (*1S,8R*)




$C_{15}H_{16}O_6$
(*3S,5R*)-1-Ethynyl-2-methyl-3,5-bis[(vinyloxy)carbonyloxy]-1-cyclohexene

$[\alpha]_D^{20} = -112$ (*c* 0.65, CHCl₃)

Source of chirality: (*S*)-(+) -carvone

Absolute configuration: 3*S*,5*R*




$C_{15}H_{16}O_6$
(*3R,5S*)-1-Ethynyl-2-methyl-3,5-bis[(vinyloxy)carbonyloxy]-1-cyclohexene

$[\alpha]_D^{20} = +108$ (*c* 0.85, CHCl₃)

Source of chirality: (*R*)-(−) -carvone

Absolute configuration: 3*R*,5*S*




$C_{15}H_{16}O_6$
(*3S,5S*)-1-Ethynyl-2-methyl-3,5-bis[(vinyloxy)carbonyloxy]-1-cyclohexene

$[\alpha]_D^{20} = -41$ (*c* 0.57, CHCl₃)

Source of chirality: (*R*)-(−) -carvone

Absolute configuration: 3*S*,5*S*




(3S,5R)-1-Ethynyl-3-hydroxy-2-methyl-5-[(vinyloxy)carbonyloxy]-1-cyclohexene

[α]_D²⁰ = -45 (c 0.35, CHCl₃)

Source of chirality: (S)-(+) -carvone

Absolute configuration: 3S,5R




(3R,5S)-1-Ethynyl-3-hydroxy-2-methyl-5-[(vinyloxy)carbonyloxy]-1-cyclohexene

[α]_D²⁰ = +50 (c 0.58, CHCl₃)

Source of chirality: (R)-(−) -carvone

Absolute configuration: 3R,5S




(3R,5R)-1-Ethynyl-3-hydroxy-2-methyl-5-[(vinyloxy)carbonyloxy]-1-cyclohexene

[α]_D²⁰ = +51 (c 0.8, CHCl₃)

Source of chirality: (S)-(+) -carvone

Absolute configuration: 3R,5R



(3S,5R)-1-Ethynyl-5-hydroxy-2-methyl-3-[(vinyloxy)carbonyloxy]-1-cyclohexene


[α]_D²⁰ = -104 (c 0.31, CHCl₃)

Source of chirality: (S)-(+) -carvone

Absolute configuration: 3S,5R

Daniel Oves, Vicente Gotor-Fernández, Susana Fernández,
Miguel Ferrero and Vicente Gotor*

Tetrahedron: Asymmetry 15 (2004) 2881



(3*R*,5*R*)-1-Ethynyl-5-hydroxy-2-methyl-3-[(vinyloxy)carbonyloxy]-1-cyclohexene


[α]_D²⁰ = +42 (*c* 0.63, CHCl₃)

Source of chirality: (*S*)-(+) -carvone

Absolute configuration: 3*R*,5*R*

Daniel Oves, Vicente Gotor-Fernández, Susana Fernández,
Miguel Ferrero and Vicente Gotor*

Tetrahedron: Asymmetry 15 (2004) 2881



(3*R*,5*R*)-3-[(Acetonoxime)carbonyloxy]-1-ethynyl-5-hydroxy-2-methyl-1-cyclohexene

[α]_D²⁰ = +57 (*c* 0.5, CHCl₃)

Source of chirality: (*S*)-(+) -carvone

Absolute configuration: 3*R*,5*R*

Giuseppe Guanti,* Luca Banfi, Andrea Bassi, Elisabetta Bevilacqua,
Laura Bondanza and Renata Riva


Tetrahedron: Asymmetry 15 (2004) 2889

Ee = 96.0% [by NMR or HPLC of Mosher's double ester]

[α]_D²⁵ = +5.5 (*c* 20, CHCl₃)

Source of chirality: enzymatic double kinetic resolution/Mitsunobu inversion

Absolute configuration; *R* (assigned by chemical correlation)



3-*O*-Benzyl-*sn*-glycerol

Michael Larsson, Jimmy Andersson, Rong Liu and
Hans-Erik Höglberg*

Tetrahedron: Asymmetry 15 (2004) 2907


Ee >99%; dr >99:1

[α]_D²⁵ = +55.0 (*c* 2.0, CHCl₃)


[α]₅₇₈²⁵ = +57.3 (*c* 2.0, CHCl₃)

Source of chirality: ex-chiral pool synthesis combined with enzymatic isomer separation

Absolute configuration: (2*S*,3*S*)



(2*S*,3*S*)-3-Methyl-4-(phenylsulfanyl)butan-2-ol




C₁₁H₁₄O₂S
(S)-2-Methyl-3-(phenylsulfanyl)propionic acid methyl ester

Ee >97%

[α]_D²⁵ = -63.6 (c 1.6, CHCl₃)

Source of chirality: ex-chiral pool synthesis

Absolute configuration: (2S)




C₁₀H₁₄OS
(S)-2-Methyl-3-(phenylsulfanyl)propan-1-ol

Ee >97%

[α]_D²⁵ = +15.3 (c 2.0, CHCl₃)

Source of chirality: ex-chiral pool synthesis

Absolute configuration: (2S)



C₁₇H₃₀OSSi
(1S,2S)-tert-Butyl-(1,2-dimethyl-3-(phenylsulfanyl)propoxy)-dimethylsilane


Ee >99%; dr >99:1

[α]₅₇₈²⁵ = +41.1 (c 2.0, CHCl₃)

[α]₅₄₆²⁵ = +46.8 (c 2.0, CHCl₃)

Source of chirality: ex-chiral pool synthesis combined with enzymatic isomer separation

Absolute configuration: (1S,2S)



C₁₇H₃₀O₃SSi
(1S,2S)-tert-Butyl-(1,2-dimethyl-3-(phenylsulfonyl)propoxy)-dimethylsilane


Ee >99%; dr >99:1

[α]₅₇₈²⁵ = +16.0 (c 2.6, CHCl₃)

[α]₅₄₆²⁵ = +18.1 (c 2.6, CHCl₃)

Source of chirality: ex-chiral pool synthesis combined with enzymatic isomer separation


Absolute configuration: (1S,2S)



C₁₆H₃₄O
(2*S*,3*R*)-3-Methylpentadecan-2-ol


Ee >99%; dr >99:1
 $[\alpha]_{578}^{25} = +18.3$ (*c* 2.2, *n*-hexane)
 $[\alpha]_{546}^{25} = +20.8$ (*c* 2.2, *n*-hexane)

Source of chirality: ex-chiral pool synthesis combined with enzymatic isomer separation
 Absolute configuration: (2*S*,3*R*)




C₁₂H₂₃NO₃
N-Boc-piperidine-2-ethanol

Ee 90%
 $[\alpha]_D^{25} = +19.3$ (*c* 1, CHCl₃)



C₁₂H₂₁NO₃
2-(2-Oxo-ethyl)-piperidine-1-carboxylic acid *tert*-butyl ester

Ee 90%
 $[\alpha]_D^{25} = +48.0$ (*c* 1, CHCl₃)




C₁₄H₂₁NO₃
2-(2-Oxo-but-3-ynyl)-piperidine-1-carboxylic acid *tert*-butyl ester

Ee 90%
 $[\alpha]_D^{25} = -30$ (*c* 1, CHCl₃)

Alessio Barilli, Francesca Belinghieri, Daniele Passarella,*
 Giordano Lesma, Sergio Riva,* Alessandra Silvani and
 Bruno Danieli

Tetrahedron: Asymmetry 15 (2004) 2921




Ee 90%
 $[\alpha]_D^{25} = -32.5$ (*c* 1, CHCl₃)

2-(2-Oxo-4-trimethylsilyl-but-3-ynyl)-piperidine-1-carboxylic acid *tert*-butyl ester

Alessio Barilli, Francesca Belinghieri, Daniele Passarella,*
 Giordano Lesma, Sergio Riva,* Alessandra Silvani and
 Bruno Danieli

Tetrahedron: Asymmetry 15 (2004) 2921




Ee 90%
 $[\alpha]_D^{25} = -46$ (*c* 1, CHCl₃)

2-[2-Benzyl-6-oxo-1,4,5,6-tetrahydro-pyridin-3-yl]-2-oxo-ethyl]-piperidine-1-carboxylic acid *tert*-butyl ester

Alessio Barilli, Francesca Belinghieri, Daniele Passarella,*
 Giordano Lesma, Sergio Riva,* Alessandra Silvani and
 Bruno Danieli

Tetrahedron: Asymmetry 15 (2004) 2921




Ee 90%
 $[\alpha]_D^{25} = +162$ (*c* 1, CHCl₃)

1-Benzyl-2-oxo-6-piperidin-2-yl-1,2,3,4,6,7,8,8a-octahydro-quinoline-8-carboxylic acid methyl ester

Alessio Barilli, Francesca Belinghieri, Daniele Passarella,*
 Giordano Lesma, Sergio Riva,* Alessandra Silvani and
 Bruno Danieli

Tetrahedron: Asymmetry 15 (2004) 2921




Ee 90%
 $[\alpha]_D^{25} = +14$ (*c* 1, CHCl₃)

1-Benzyl-8-hydroxymethyl-6-piperidin-2-yl-1,2,3,4,6,7,8,8a-octahydro-1*H*-quinoline

Alessio Barilli, Francesca Belinghieri, Daniele Passarella,*
 Giordano Lesma, Sergio Riva,* Alessandra Silvani and
 Bruno Danieli

Tetrahedron: Asymmetry 15 (2004) 2921




N-Benzyl-aloperine

Ee 90%
 $[\alpha]_D^{25} = +56$ (*c* 0.7, EtOH)

Alessio Barilli, Francesca Belinghieri, Daniele Passarella,*
 Giordano Lesma, Sergio Riva,* Alessandra Silvani and
 Bruno Danieli

Tetrahedron: Asymmetry 15 (2004) 2921




(+)-Aloperine

Ee 90%
 $[\alpha]_D^{25} = +68$ (*c* 1, EtOH)

Lahssen El Blidi, Dominique Crestia, Estelle Gallienne,
 Colette Demuynck, Jean Bolte and Marielle Lemaire*

Tetrahedron: Asymmetry 15 (2004) 2951




6-Amino-1-hydroxymethylcyclohexane-1,2,3-triol

$[\alpha]_D^{25} = -5$ (*c* 2.5, MeOH)
 Source of chirality: fructose-1,6-diphosphate
 aldolase from rabbit muscle
 Absolute configuration: 1*S*,2*S*,3*R*,6*R*


Lahssen El Blidi, Dominique Crestia, Estelle Gallienne,
 Colette Demuynck, Jean Bolte and Marielle Lemaire*

Tetrahedron: Asymmetry 15 (2004) 2951




1-Hydroxymethyl-6-nitrocyclohexane-1,2,3-triol

$[\alpha]_D^{25} = -3.9$ (*c* 1.4, MeOH)
 Source of chirality: fructose-1,6-diphosphate
 aldolase from rabbit muscle
 Absolute configuration: 1*S*,2*S*,3*R*,6*R*




$C_{10}H_{11}ClO_3$
Methyl (*R*)-(+)2-(4-chlorophenoxy)propanoate

Ee = 97%
 $[\alpha]_D^{20} = +44.7$ (*c* 0.94, EtOH)
 Source of chirality: biotransformation
 Absolute configuration: *R*




$C_{10}H_{12}O_2S$
Methyl (*R*)-(+)2-phenylthiopropanoate

Ee = 93%
 $[\alpha]_D^{23} = +145.7$ (*c* 1.02, EtOH)
 $[\alpha]_D^{22} = +141.2$ (*c* 0.68, acetone)
 Source of chirality: biotransformation
 Absolute configuration: *R*




$C_{11}H_{14}O_2$
Methyl (*S*)-(+)2-methyl-3-phenylpropanoate

Ee = 88%
 $[\alpha]_D^{25} = +39.3$ (*c* 0.95, MeOH)
 Source of chirality: biotransformation
 Absolute configuration: *S*



$C_{10}H_{13}NO_2$
Methyl (*R*)-(+)2-phenylaminopropanoate

Ee = >99%
 $[\alpha]_D^{22} = +84.6$ (*c* 0.53, MeOH)
 Source of chirality: biotransformation
 Absolute configuration: *R*




Ee = 90%

 $[\alpha]_D^{21} = +140.2$ (*c* 1.00, MeOH)

Source of chirality: biotransformation

Absolute configuration: *R* $C_{10}H_{11}ClO_2S$ Methyl (*R*)-(+)2-(4-chlorophenylthio)propanoate

Ee = 99.6%

 $[\alpha]_D = -15.4$ (*c* 0.84, MeOH) $C_{11}H_{22}O_2$

(R)-2-Methyldecanoic acid